Finanzen von Pasithea Therapeutics Corp (KTTA)KTTAPasithea Therapeutics Corp

Evaluating the bottom line, Pasithea Therapeutics Corp maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -65.49%, provide a clear picture of how effectively KTTA converts its operational activities into shareholder value.

In the context of the broader market, KTTA competes directly with industry leaders such as RKTO and PBM. With a market capitalization of $19.23M, it holds a leading position in the sector. When comparing efficiency, KTTA's gross margin of N/A stands against RKTO's N/A and PBM's N/A. Such benchmarking helps identify whether Pasithea Therapeutics Corp is trading at a premium or discount relative to its financial performance.

The company has consistently reported negative net income, with the most recent figure being -5,273,852 USD for Q2 2026. The forward P/E ratio is currently 0, indicating no earnings expected in the near term, which reflects ongoing financial challenges.